Insulet Corp

Most Recent

  • uploads///diabetes _
    Company & Industry Overviews

    Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump

    Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.

    By Sarah Collins
  • uploads///animas exit from insulin pump business
    Company & Industry Overviews

    Tandem Diabetes Care’s International Expansion Strategy

    Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.

    By Sarah Collins
  • uploads///insulin syringe _
    Company & Industry Overviews

    Analysts’ Views on Tandem Diabetes Care after Its FDA Approval

    After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump.

    By Sarah Collins
  • uploads///strategy
    Company & Industry Overviews

    Johnson & Johnson Accepts Sale of Its LifeScan Business

    On June 12, Johnson & Johnson (JNJ) announced it had accepted a $2.1 billion offer for the sale of its LifeScan business, which manufactures blood glucose monitoring devices and OneTouch products, from private equity company Platinum Equity.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Tandem Diabetes Care’s Stock Performance This Month

    On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.

    By Sarah Collins
  • uploads///AdobeStock_
    Earnings Report

    Why Insulet Stock Is Soaring after Q2 Results

    Insulet (PODD) stock has risen 19.27% today to $140.65, soaring in response to the company’s strong second-quarter results yesterday.

    By Margaret Patrick
  • uploads///stairway _
    Company & Industry Overviews

    What Are Insulet’s Key Growth Drivers in 2019?

    In the first quarter, Insulet (PODD) secured coverage for its Omnipod devices for 5 million Medicare and Medicaid members.

    By Margaret Patrick
  • uploads///earth _
    Company & Industry Overviews

    Analyzing Tandem Diabetes and Insulet’s International Strategy

    Tandem Diabetes Care (TNDM) reaffirmed its fiscal 2019 international market revenue guidance of $45 million to $50 million.

    By Margaret Patrick
  • uploads///diabetes _
    Company & Industry Overviews

    Tandem or Insulet: Who Is Reporting Faster Pump Uptake?

    In the first quarter, Tandem Diabetes Care (TNDM) shipped 14,700 insulin pumps, a YoY rise of 232%.

    By Margaret Patrick
  • uploads///arrows _
    Company & Industry Overviews

    Tandem Diabetes and Insulet: Comparing Revenue Growth

    In its first-quarter earnings conference call, Tandem Diabetes Care (TNDM) increased its fiscal 2019 revenue guidance.

    By Margaret Patrick
  • uploads///diabetes _
    Company & Industry Overviews

    How Analysts Rate Tandem Diabetes Care and Insulet

    Until the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic and Johnson & Johnson.

    By Margaret Patrick
  • uploads///diabetes _
    Company & Industry Overviews

    Why Tandem Diabetes Care Stock Soared Over 1,480% in 2018

    Tandem Diabetes Care (TNDM) stock grew from $2.36 on December 29, 2017, to reach $37.31 at the close of market on December 28, 2018, an increase of ~1,481% this year.

    By Daniel Collins
  • uploads///equipment _
    Company & Industry Overviews

    Tandem Diabetes Care Stock Has Skyrocketed in 2018

    On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.

    By Daniel Collins
  • uploads///TNDM
    Company & Industry Overviews

    Why Wall Street Is Still Bullish on Tandem Stock

    This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.

    By Kenneth Smith
  • uploads///diabetes _
    Company & Industry Overviews

    Why Tandem Should Be on Your Stock Radar

    Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.

    By Kenneth Smith
  • uploads///Diabetes
    Company & Industry Overviews

    A Look into Johnson & Johnson’s Diabetes Care Business

    In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.

    By Daniel Collins
  • uploads///diabetes _
    Company & Industry Overviews

    Why TNDM’s Stock Price Rose 7.4% on September 25

    On September 25, Tandem Diabetes Care’s stock price closed at $47.84, which represents ~7.43% growth from the close of $44.53 on September 24.

    By Daniel Collins
  • uploads///Diabetes
    Company & Industry Overviews

    MDT’s Diabetes Business Could Significantly Boost Its Revenue

    In fiscal Q4 2018, Medtronic’s (MDT) Diabetes segment generated revenue of $645 million compared to $512 million in fiscal 2017.

    By Daniel Collins
  • uploads///ABMD RD
    Company & Industry Overviews

    Why Abiomed’s Product Pipeline Looks Promising

    Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps.

    By Kenneth Smith
  • uploads///heartbeat _
    Company & Industry Overviews

    What Analysts Recommend for Abiomed and Peers in February 2018

    Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///hospice _
    Company & Industry Overviews

    Analysts’ Ratings for NxStage Medical and Peers in February 2018

    NxStage Medical sells its products and offers services in three markets: home, critical care, and in-center.

    By Kenneth Smith
  • uploads///DIABETES
    Company & Industry Overviews

    JNJ Exits Insulin Pump Business amid Stiff Competition

    On October 5, 2017, & Johnson’s (JNJ) diabetes care company, Animas, announced its plans to exit the insulin pump business.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Medtronic Saw Several Challenges during Launch of MiniMed 670G

    In fiscal 2H17, Medtronic launched the priority access program to first target those patients who were interested in purchasing MiniMed 670G.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What’s Medtronic’s Long-Term Growth Strategy for Its Diabetes Business?

    Medtronic (MDT) expects its diabetes business to witness a temporary sequential drop in revenues in 2Q18 and then return back to growth in the second half of fiscal 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What’s Medtronic’s Strategy to Drive Growth in Diabetes Group?

    In the US, Medtronic has entered outcomes-based contracts with UnitedHealth Group and Aetna.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Medtronic Aims to Become a Holistic Diabetes Management Company

    Medtronic (MDT) is currently a leading supplier of insulin pumps and sensors to type one diabetes patients in the US.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Affected the Performance of Medtronic’s Diabetes Franchise?

    Medtronic (MDT) has been witnessing higher-than-anticipated demand for its automated insulin dosing technology around the world.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    Dexcom Tanks on Profit Booking after Directors Increase Stakes

    Dexcom (DXCM) was the worst-performing stock within the iShares U.S. Medical Devices ETF (IHI) on May 26, 2016.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Profit Booking Leaves the iShares US Medical Devices ETF (IHI) in the Red

    On May 19, markets declined, with the SPDR S&P 500 ETF dropping by 0.3% and the iShares US Medical Devices ETF (IHI) declining by 0.8%.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.